<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02137096</url>
  </required_header>
  <id_info>
    <org_study_id>IRB201400316</org_study_id>
    <secondary_id>PEDS006</secondary_id>
    <nct_id>NCT02137096</nct_id>
  </id_info>
  <brief_title>Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma</brief_title>
  <official_title>High Dose Conditioning With Ifosfamide, Carboplatin, and Etoposide With Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study to evaluate the response rates for patients undergoing high dose
      conditioning chemotherapy using Etoposide, Carboplatin and Ifosfamide followed by autologous
      stem cell transplantation for the treatment of recurrent Nasopharyngeal Cancer (NPC) in
      children, adolescents, and young adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The use of high dose chemotherapy followed by autologous peripheral blood stem cell (PBSC)
      transplantation in recurrent nasopharyngeal carcinoma has shown promise when compared with
      standard chemotherapy. This study has been designed to evaluate response rates and toxicities
      associated with undergoing high dose conditioning with Etoposide, Carboplatin and Ifosfamide
      followed by autologous stem cell transplantation support in the treatment of recurrent
      nasopharyngeal carcinoma in children, adolescents, and young adults.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2014</start_date>
  <completion_date type="Actual">May 9, 2017</completion_date>
  <primary_completion_date type="Actual">May 9, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the tumor response</measure>
    <time_frame>12 months after completion of treatment</time_frame>
    <description>To evaluate the response rates for patients undergoing high dose conditioning using Etoposide, Carboplatin and Ifosfamide followed by autologous stem cell transplantation for the treatment of recurrent NPC in children, adolescents, and young adults.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment related Toxicity</measure>
    <time_frame>60 months after treatment</time_frame>
    <description>To evaluate the toxicities associated with undergoing high dose conditioning using Etoposide, Carboplatin and Ifosfamide followed by autologous stem cell transplantation for the treatment of recurrent NPC in children, adolescents, and young adults</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1</enrollment>
  <condition>Recurrent Nasopharynx Carcinoma</condition>
  <arm_group>
    <arm_group_label>High Dose Conditioning</arm_group_label>
    <description>Single arm - receives high dose Etoposide phosphate, Ifosfamide, and Carboplatin followed by Autologous Stem Cell Transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide phosphate</intervention_name>
    <description>Etoposide is one of three drugs used in the high-dose conditioning phase</description>
    <arm_group_label>High Dose Conditioning</arm_group_label>
    <other_name>Etopophos</other_name>
    <other_name>Toposar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin is one of the drugs used in the high-dose conditioning phase.</description>
    <arm_group_label>High Dose Conditioning</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
    <description>Ifosfamide is one of the drugs used in the high-dose conditioning phase</description>
    <arm_group_label>High Dose Conditioning</arm_group_label>
    <other_name>Ifex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous Stem Cell Transplantation</intervention_name>
    <description>Autologous Stem Cell Transplantation follows the high-dose chemotherapy phase of the arm.</description>
    <arm_group_label>High Dose Conditioning</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      hematopoietic stem cells
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pediatric patients with Imaging and tissue diagnosis of recurrent or progressive
        nasopharyngeal carcinoma.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Imaging and tissue diagnosis of recurrent or progressive nasopharyngeal carcinoma

          -  Documentation of previous treatment including conventional chemotherapy and/or
             radiation therapy as clinically appropriate

          -  Ages 2 to 30 years of age

          -  Negative serum pregnancy test if applicable

          -  Calculated creatinine clearance of greater than 60 mL/minute, serum creatinine of less
             than 12o micromoles/L, total bilirubin less than 2 mg/dL and aspartate
             aminotransferase (AST) must be less than twice the upper limit of normal

        Exclusion Criteria:

          -  Unsuitable candidate for autologous transplantation due to comorbidities or
             intractable psychosocial issues

          -  Pregnancy

          -  Breast-feeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Fort, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UF Health Shands Hospital</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2014</study_first_submitted>
  <study_first_submitted_qc>May 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2014</study_first_posted>
  <last_update_submitted>June 13, 2017</last_update_submitted>
  <last_update_submitted_qc>June 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Recurrent nasopharynx carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

